Docoh
Loading...

NAVB Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products based on its Manocept™ platform to enhance patient care by identifying the sites and pathways of disease and enable better diagnostic accuracy, clinical decision-making, and targeted treatment. Navidea's Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company's pipeline through global partnering and commercialization efforts.

Company profile

Ticker
NAVB
Exchange
Website
CEO
Jed Latkin
Employees
Incorporated
Location
Fiscal year end
Former names
NEOPROBE CORP
SEC CIK
IRS number
311080091

NAVB stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

13 May 21
29 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 7.51M 7.51M 7.51M 7.51M 7.51M 7.51M
Cash burn (monthly) (positive/no burn) (positive/no burn) 1.11M 949.4K 1.02M 857.08K
Cash used (since last report) n/a n/a 4.39M 3.76M 4.04M 3.39M
Cash remaining n/a n/a 3.11M 3.75M 3.47M 4.11M
Runway (months of cash) n/a n/a 2.8 3.9 3.4 4.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
26 Jul 21 Malcolm G Witter Common Stock Buy Aquire P No No 1.698 15,000 25.47K 78,257
30 Jun 21 Amit Bhalla Common Stock Grant Aquire A No No 0 2,409 0 4,909
30 Jun 21 Bruck Claudine Common Stock Grant Aquire A No No 0 3,969 0 16,519
30 Jun 21 Sarah Kathryn Rouan Common Stock Grant Aquire A No No 0 4,892 0 18,242

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: Academy, accredited, adjudicate, anniversary, anticancer, book, ceased, Certificate, clarify, comment, cumulative, dataset, disposed, diversity, dramatically, exceed, extinguishment, factual, falling, Food, formal, forthcoming, freestanding, fringe, hearing, holder, immunological, immunology, Immunotherapy, implemented, inadvisable, indemnify, inventory, involuntary, led, mouse, Northwestern, offeree, Official, Paycheck, payload, Preemptive, privilege, proinflammatory, prosecution, prospectively, Reload, repayment, reproducible, respond, retrospective, route, SC, show, statistical, suggested, superior, suspending, synergized, syngeneic, thereof, toxicity, Type, UK, unsatisfactory, violate, vivo, voluntary, winding
Removed: absorption, affinity, alter, alternative, alternatively, AMT, annum, autoimmune, binding, biopsy, Boston, brought, cancellation, categorized, classically, closed, closely, comparator, corporate, CRC, CROI, deadline, Deficiency, demonstrating, deplete, discontinued, distancing, driven, effecting, emergency, employing, Englewood, epidemic, exclusively, execution, expired, flow, foundation, globally, guaranteed, illiquidity, impacting, improvement, instability, Institute, irrespective, Jersey, justify, leased, leverage, limiting, liver, low, lymphatic, manner, marketed, metastatic, Miami, modulate, morale, motivate, NCI, node, noted, occurrence, oncology, originally, overhead, peripheral, personnel, phenotype, positive, precluding, presently, preventative, production, productive, productivity, protect, quantify, quarantine, radioactive, raw, reached, recurrence, reducing, reduction, reference, refund, refundable, refunded, regained, regular, relaxed, repealed, retain, return, semiquantitative, shelf, simultaneously, specific, specificity, split, staging, stating, sublicensed, submitting, substantial, sufficiently, Summit, Sylvan, tested, timeframe, trade, transport, treating, visit, warrant, website

Patents

APP
Utility
Compositions and Related Methods for Blocking Off-target Localization of Mannosylated Dextrans and Other CD206 Ligands
20 May 21
Disclosed is a method for increase target specificity of a mannosylated dextran therapeutic or diagnostic compound by administering at least a blocking composition comprising a backbone and one or more CD206 targeting moieties attached thereto; administering an effective amount of the mannosylated dextran therapeutic or diagnostic compound comprising a dextran backbone and one or more CD206 targeting moieties and one or more therapeutic agents attached thereto.
GRANT
Utility
Compounds and methods for diagnosis and treatment of viral infections
18 May 21
Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein.
APP
Utility
Compositions and Related Methods for the Ablation of M2 Macrophages and Myeloid Derived Suppressor Cells
25 Feb 21
Compositions and methods for ablating CD206 expressing macrophages and/or CD206 expressing myeloid derived suppressor cells (MDSCs) are disclosed.
APP
Utility
Compositions and Methods for Altering Macrophage Phenotype
30 Sep 20
Disclosed are methods and compositions for repolarizing a tumor associated macrophage (TAM) from M2 to M1 comprising administering to a subject in need thereof an effective dose of a compound comprising a dextran backbone and one or more CD206 targeting moieties conjugated thereto.
APP
Utility
Compositions and Methods for Assessing Macrophage Mediated Pathology
29 Jul 20
Compositions and methods are disclosed for assessing macrophage involvement in the inflammation of one or more joints of a subject.